Cargando…
信迪利单抗致肺癌患者免疫性血小板减少1例并文献复习
Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induce...
Autores principales: | CAI, Jingjing, YANG, Guangxia, ZHANG, Xuemei, LIU, Linlin, YAN, Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600748/ https://www.ncbi.nlm.nih.gov/pubmed/37985158 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32 |
Ejemplares similares
-
利妥昔单抗治疗脾边缘区淋巴瘤致急性血小板减少一例报告并文献复习
Publicado: (2021) -
多种抗凝剂诱导的假性血小板减少一例报告并文献复习
Publicado: (2015) -
伴血小板减少MYH9相关性疾病一例并文献复习
Publicado: (2020) -
血小板计数检测在成人慢性原发免疫性血小板减少症利妥昔单抗疗效预测中的价值
Publicado: (2018) -
利妥昔单抗治疗IgA型温抗体型自身免疫性溶血性贫血一例报告并文献复习
Publicado: (2018)